A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study-Reference-Cited by-同舟云学术

A Nationwide Survey on Patient’s versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study

Published:2016-11-28 Issue:11 Volume:11 Page:e0166607
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

De Mits Sophie^ORCID,Lenaerts Jan,Vander Cruyssen Bert,Mielants Herman,Westhovens René,Durez Patrick,Elewaut Dirk,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference22 articles.

1. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biological therapy;J Barton;Patient preference and adherence,2009

2. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate;R Rau;Scandinavian Journal of Rheumatology,2004

3. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience;W Demary;Patient preference and adherence,2014

4. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate;MC Genovese;Arthritis and rheumatism,2011

5. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab;PC Taylor;The Journal of rheumatology,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis;Musculoskeletal Care;2024-05

2. Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system;Revista de Saúde Pública;2023-07-19

3. Need to assess the effect of therapy? Ask the patient!;Rheumatology Science and Practice;2023-06-29

4. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring;Scandinavian Journal of Gastroenterology;2023-02-17

5. Perceived treatment satisfaction in patients with systemic rheumatic diseases treated with biologic therapies: results of a self-reported survey;Rheumatology International;2023-02-14